{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-301829","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2023-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.175628+00:00","generated_at":"2026-06-07T08:20:39.558310+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tyra Biosciences dosed first patient in SURF201 for TYRA-200; TYRA-300 Part A clears dose cohorts; plans ACH IND H2 2024","bullets":["First patient dosed in SURF201 Phase 1 study of TYRA-200 for FGFR2-altered cholangiocarcinoma and advanced solid tumors.","SURF301 Part A dose escalation cleared multiple cohorts above anticipated dose for Phase 2 achondroplasia study.","Expansion cohorts in SURF301 Part B at dose levels anticipated for oncology evaluation.","Tyra plans to submit initial SURF301 Phase 1 results for a scientific congress in 2024.","Company plans to submit IND for TYRA-300 in pediatric achondroplasia in H2 2024, starting with ages 5-12."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-301829","json":"https://secwatch.observer/filing/0001193125-23-301829.json","markdown":"https://secwatch.observer/filing/0001193125-23-301829.md","text":"https://secwatch.observer/filing/0001193125-23-301829.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000119312523301829/0001193125-23-301829-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000119312523301829/d489661d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T08:20:39.558310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}